Europe has a plan to insulate itself from drug shortages, which the U.S. could also benefit from — unless tariffs get in the ...

Based on the reciprocal tariff approach, a 10% tariff on Indian pharma imports could be a possibility, but BofA cites a few ...

Generic drugmakers and hospital pharmacists warn that added financial pressure from tariffs could strain the nation's generic ...

A study linking Indian generic drugs to a higher risk of serious side effects in the US has spurred backlash from the Indian ...

Large mergers and acquisitions in the Indian pharmaceutical market are unlikely soon due to various uncertainties, says GV ...

An analysis by Pharmarack, a market research firm, showed that 226 vildagliptin (anti-diabetic) brands are now available in ...

Empagliflozin, which in addition to treating type-2 diabetes, also aids weight loss, and reduces cardiovascular and kidney ...

"We do not see headwinds happening in terms of any asset quality on account of tariff related issues," Setty says.

Two companies have received approved for a generic of the 2.5 mg tablet of anticoagulant rivaroxaban, which is used to reduce ...

Generic versions of diabetes drug Empagliflozin launched in India, crashing prices by 80-90% on day one post-patent expiry.

Asserting that quality standards are not region-dependent, the Indian Pharmaceutical Alliance (IPA) on Wednesday refuted the ...